Ämnen: Farmaci

Breztri Aerosphere significantly reduced rate of moderate or severe COPD exacerbations in Phase III ETHOS trial

24 Juni 2020 20:18

Full results from the positive Phase III ETHOS trial showed AstraZeneca’s triple-combination therapy Breztri Aerosphere (budesonide/glycopyrronium/formoterol fumarate) demonstrated a statistically significant reduction in the rate of moderate or severe exacerbations compared with two dual-combination therapies in patients with moderate to very severe chronic obstructive pulmonary disease (COPD).

AstraZeneca to supply Europe with up to 400 million doses of Oxford University’s vaccine at no profit

13 Juni 2020 15:10

AstraZeneca has reached an agreement with Europe’s Inclusive Vaccines Alliance (IVA), spearheaded by Germany, France, Italy and the Netherlands, to supply up to 400 million doses of the University of Oxford’s COVID-19 vaccine, with deliveries starting by the end of 2020.

Calquence showed long-term efficacy and tolerability for patients with chronic lymphocytic leukaemia in two trials

12 Juni 2020 08:32

Detailed results from both the Phase II ACE-CL-001 trial and the pivotal Phase III ASCEND trial showed the long-term efficacy and tolerability of Calquence (acalabrutinib) in chronic lymphocytic leukaemia (CLL), one of the most common types of adult leukaemia

AstraZeneca to showcase leadership in treating type-2 diabetes and cardiorenal complications at ADA 2020

11 Juni 2020 08:01

AstraZeneca will present new data from the landmark Phase III DAPA-HF and DECLARE-TIMI 58 trials at the upcoming 80th American Diabetes Association (ADA) Virtual Scientific Sessions, 12-16 June 2020. The data are among 23 accepted abstracts.....

Calquence showed promising clinical improvement in majority of 19 hospitalised COVID-19 patients

5 Juni 2020 20:39

Results published in Science Immunology showed that Calquence (acalabrutinib), a Bruton’s tyrosine kinase (BTK) inhibitor, reduced markers of inflammation and improved clinical outcomes of patients with severe COVID-19 disease.1

AstraZeneca presents new data across continuum of care from its broad renal portfolio at ERA-EDTA 2020 Virtual Congress

5 Juni 2020 08:01

AstraZeneca will present new data across its broad portfolio of renal medicines. The 20 abstracts being presented, will include data on Lokelma (sodium zirconium cyclosilicate), roxadustat and Farxiga (dapagliflozin) across different stages of chronic kidney disease (CKD) and AstraZeneca’s ongoing commitment to exploring treatment options across the full continuum of renal care.

AstraZeneca takes next steps towards broad and equitable access to Oxford University’s COVID-19 vaccine

4 Juni 2020 17:01

AstraZeneca has taken the next steps in its commitment to broad and equitable global access to the University of Oxford’s COVID-19 vaccine, following landmark agreements with the Coalition for Epidemic Preparedness Innovations (CEPI), Gavi the Vaccine Alliance, and the Serum Institute of India (SII).

AstraZeneca to discover and develop novel therapies targeting RNA-modifying proteins in oncology collaboration with Accent Therapeutics

4 Juni 2020 08:03

AstraZeneca will collaborate with Accent Therapeutics to discover, develop and commercialise transformative therapeutics targeting RNA-modifying proteins (RMPs) for the treatment of cancer.
This collaboration focuses on targeting RMPs, proteins that control many aspects of RNA biology and represents a new approach for addressing the process disruptions that can lead to cancer and can cause res

Brilinta approved in the US to reduce the risk of a first heart attack or stroke in high-risk patients with coronary artery disease

1 Juni 2020 08:03

AstraZeneca’s Brilinta (ticagrelor) has been approved in the US to reduce the risk of a first heart attack or stroke in high-risk patients with coronary artery disease (CAD), the most common type of heart disease.

Lynparza recommended for approval in EU by CHMP for BRCA-mutated metastatic pancreatic cancer

1 Juni 2020 08:03

​AstraZeneca and MSD Inc., Kenilworth, N.J., US (MSD: known as Merck & Co., Inc. inside the US and Canada) today announced that Lynparza (olaparib) has been recommended for marketing authorisation in the European Union (EU) for the 1st-line maintenance treatment of patients with germline BRCA-mutated (gBRCAm) metastatic pancreatic cancer.

Imfinzi plus tremelimumab demonstrated promising clinical activity and tolerability in patients with advanced liver cancer

29 Maj 2020 14:56

Results from the global Phase II Study 22 trial testing AstraZeneca’s tremelimumab, an anti-CTLA4 antibody, added to Imfinzi (durvalumab) demonstrated promising clinical activity and tolerability in patients with advanced hepatocellular carcinoma (HCC). HCC is the most common type of liver cancer.1

Enhertu achieved a tumour response rate of 45.3% in patients with HER2-positive metastatic colorectal cancer in Phase II DESTINY-CRC01 trial

29 Maj 2020 14:53

Results from the Phase II DESTINY-CRC01 trial of AstraZeneca and Daiichi Sankyo Company, Limited (Daiichi Sankyo)’s Enhertu (trastuzumab deruxtecan) demonstrated clinically meaningful activity in patients with HER2-positive unresectable and/or metastatic colorectal cancer who received at least two prior lines of standard treatment.

Enhertu demonstrated meaningful clinical activity in patients with HER2-mutant non-small cell lung cancer in interim analysis of Phase II DESTINY-Lung01 trial

29 Maj 2020 14:42

Results from the ongoing Phase II DESTINY-Lung01 trial showed AstraZeneca and Daiichi Sankyo Company, Limited (Daiichi Sankyo)’s Enhertu (trastuzumab deruxtecan) achieved a clinically meaningful tumour response in patients with HER2-mutant (HER2m) unresectable and/or metastatic non-squamous non-small cell lung cancer (NSCLC) whose disease had progressed following one or more systemic therapies.

Enhertu significantly improved tumour response rate and overall survival in HER2-positive metastatic gastric cancer in Phase II DESTINY-Gastric01 trial

29 Maj 2020 14:09

Detailed results from the positive, registrational, randomised controlled Phase II DESTINY-Gastric01 trial showed AstraZeneca and Daiichi Sankyo Company, Limited (Daiichi Sankyo)’s Enhertu (trastuzumab deruxtecan) demonstrated a statistically significant and clinically meaningful improvement in objective response rate (ORR) and overall survival (OS), a key secondary endpoint, versus chemotherapy.

Imfinzi showed a sustained overall survival benefit in 1st-line extensive-stage small cell lung cancer in the Phase III CASPIAN trial

29 Maj 2020 14:03

Detailed results from an updated analysis of the Phase III CASPIAN trial showed AstraZeneca’s Imfinzi (durvalumab) in combination with a choice of chemotherapies, etoposide plus either carboplatin or cisplatin, demonstrated a sustained, clinically meaningful overall survival (OS) benefit for adults with extensive-stage small cell lung cancer (ES-SCLC) treated in the 1st-line setting.

Tagrisso demonstrated unprecedented disease-free survival in the adjuvant treatment of Stage IB-IIIA patients with EGFR-mutated lung cancer

28 Maj 2020 23:03

Detailed results from the Phase III ADAURA trial showed AstraZeneca’s Tagrisso (osimertinib) demonstrated a statistically significant and clinically meaningful improvement in disease-free survival (DFS) in the adjuvant treatment of patients with early-stage (IB, II and IIIA) epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) ......

AstraZeneca collaborates with ArcherDX to use personalised cancer assays to detect minimal residual disease in lung cancer trials

26 Maj 2020 08:01

Collaboration to focus on newly launched global Phase III MERMAID-1 trial for patients with resected, early-stage non-small cell lung cancer
AstraZeneca will collaborate with ArcherDX, a genomic analysis company focused on precision oncology, to use personalised cancer monitoring to detect minimal residual disease (MRD) in patients with early-stage non-small cell lung cancer (NSCLC).
ArcherD

Enhertu granted Orphan Drug Designation in the US for gastric cancer

22 Maj 2020 08:09

AstraZeneca and Daiichi Sankyo Company, Limited (Daiichi Sankyo)’s Enhertu (trastuzumab deruxtecan) has been granted Orphan Drug Designation (ODD) in the US for the treatment of patients with gastric cancer, including gastroesophageal junction cancer.

AstraZeneca advances response to global COVID-19 challenge as it receives first commitments for Oxford’s potential new vaccine

21 Maj 2020 08:16

AstraZeneca is advancing its ongoing response to address the unprecedented challenges of COVID-19, collaborating with a number of countries and multilateral organisations to make the University of Oxford’s vaccine widely accessible around the world in an equitable manner.

Lynparza approved in the US for HRR gene-mutated metastatic castration-resistant prostate cancer

20 Maj 2020 08:48

AstraZeneca and MSD Inc., Kenilworth, N.J., US (MSD: known as Merck & Co., Inc. inside the US and Canada) today announced that Lynparza (olaparib) has been approved in the US for patients with homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC).